BD, a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA) market approval for the BD Onclarity HPV Assay to be used with the ThinPrep Pap Test.
The BD SurePath Liquid-based Pap Test vial and the Hologic ThinPrep Pap Test PreservCyt Solution vial are the two most common Pap vials used by laboratories in the United States. The inclusion of the ThinPrep Pap Test improves access to the benefits of the BD human papillomavirus virus (HPV) assay, which is the only FDA-approved assay that tests for an extended set of HPV types individually, and particularly for HPV31, a specific type of HPV that poses a high-risk for causing cervical cancer. Individual identification of HPV31 can help better determine risk for cervical pre-cancer, which may lead health care providers to different clinical decision-making than when assessing risk when multiple genotypes are reported collectively.
Also Read: Modular Devices Invests In Interim Diagnostic Imaging
“Most tests report multiple HPV types in a single pooled result, which can mask the true risk of developing cervical cancer,” said Brooke Story, worldwide president of Integrated Diagnostics Solutions for BD. “Being able to identify high-risk HPV31 individually is critical to the detection and prevention of cervical cancer. HPV31 poses the second-highest risk for cervical pre-cancer, and the BD Onclarity™ HPV Assay is the only FDA-approved assay that screens for it individually.”
This important milestone supports BD’s strategy to penetrate the large and growing molecular diagnostics market through its expanded installed base and providing additional testing solutions for women’s health.
The BD Onclarity™ HPV Assay has FDA approval for use in vaccinated women. As the previously vaccinated subpopulation ages, the screening population will progressively include women with reduced prevalence of HPV 16 and 18, increasing the value of extended genotype reporting in a mixed population of vaccinated and unvaccinated women.
SOURCE: PR Newswire